TY - JOUR
T1 - RB1 alteration and poor prognosis in women with high-grade neuroendocrine carcinoma of the uterine cervix
T2 - a NeCTuR study
AU - Legarreta, Alejandra Flores
AU - Salvo, Gloria
AU - Gonzales, Naomi R.
AU - Chisholm, Gary
AU - Hillman, R. Tyler
AU - Frumovitz, Michael
N1 - Funding Information:
This study was supported by the National Cancer Institute under award number P30CA016672, which supports the MD Anderson Cancer Center Clinical Trials Office, and by Small/Large Cell Carcinoma of the Cervix: Sisters United.
Publisher Copyright:
© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.
PY - 2023/7
Y1 - 2023/7
N2 - Objective: To describe the gene alteration status in high-grade neuroendocrine cervical carcinoma (NECC) specimens and to explore the potential association of unique gene alterations with survival. Methods: Results from tumor-based molecular testing on specimens from women with high-grade NECC in the Neuroendocrine Cervical Tumor Registry were reviewed and analyzed. Tumor specimens could be from primary or metastatic sites and obtained at initial diagnosis, during treatment, or at recurrence. Results: Molecular testing results were available for 109 women with high-grade NECC. The genes most frequently mutated were PIK3CA (mutated in 18.5% of patients), TP53 (17.4%), and MYC (14.5%). Other targetable alterations identified were alterations in KIT (7.3%), KRAS (7.3%), and PTEN (7.3%). Women with tumors having an RB1 alteration (6.4%) had a median overall survival (OS) of 13 months, compared to 26 months for women with tumors that did not have an RB1 alteration (p=0.003). None of the other genes evaluated were shown to be associated with OS. Conclusion: Although no individual alteration was found in a majority of tumor specimens from patients with high-grade NECC, a large proportion of women with this disease will have at least one targetable alteration. Treatments based on these gene alterations may offer additional targeted therapies for women with recurrent disease, who currently have very limited therapeutic options. Patients with tumors that harbor RB1 alterations have decreased OS.
AB - Objective: To describe the gene alteration status in high-grade neuroendocrine cervical carcinoma (NECC) specimens and to explore the potential association of unique gene alterations with survival. Methods: Results from tumor-based molecular testing on specimens from women with high-grade NECC in the Neuroendocrine Cervical Tumor Registry were reviewed and analyzed. Tumor specimens could be from primary or metastatic sites and obtained at initial diagnosis, during treatment, or at recurrence. Results: Molecular testing results were available for 109 women with high-grade NECC. The genes most frequently mutated were PIK3CA (mutated in 18.5% of patients), TP53 (17.4%), and MYC (14.5%). Other targetable alterations identified were alterations in KIT (7.3%), KRAS (7.3%), and PTEN (7.3%). Women with tumors having an RB1 alteration (6.4%) had a median overall survival (OS) of 13 months, compared to 26 months for women with tumors that did not have an RB1 alteration (p=0.003). None of the other genes evaluated were shown to be associated with OS. Conclusion: Although no individual alteration was found in a majority of tumor specimens from patients with high-grade NECC, a large proportion of women with this disease will have at least one targetable alteration. Treatments based on these gene alterations may offer additional targeted therapies for women with recurrent disease, who currently have very limited therapeutic options. Patients with tumors that harbor RB1 alterations have decreased OS.
KW - Cervical Cancer
KW - Neuroendocrine Carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85164244979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164244979&partnerID=8YFLogxK
U2 - 10.3802/jgo.2023.34.e50
DO - 10.3802/jgo.2023.34.e50
M3 - Article
C2 - 36807750
AN - SCOPUS:85164244979
SN - 2005-0380
VL - 34
JO - Journal of gynecologic oncology
JF - Journal of gynecologic oncology
IS - 4
M1 - e50
ER -